Wire · technology
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for ...
◆ Sectors
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
Insilico Medicine has nominated ISM0900, an AI-designed oral inhibitor targeting lipoprotein(a) (Lp(a)), as a preclinical candidate for cardiovascular risk management. This drug candidate shows potent, selective inhibition of Lp(a), addressing a major unmet need in cardiovascular therapy, and marks a significant advance driven by generative AI in early-stage drug discovery.
This Wire brief sits within Fusion42's coverage of Drug Discovery, AI Frontier Models and Biotech.
◆ ◆ The Wire takeaway
You have a new chance to address a huge cardiovascular market gap with AI-designed oral therapies that get from concept to preclinical candidate in 12-18 months. Stand out by focusing development on safe, rapid-onset, and selective Lp(a) inhibitors that current drugmakers lack.
◆ Coverage
1 source · 12 Aug 2026
◆ Related on Wire
◆ Topics